$200 million support from Novo Nordisk to the fight against diabetes

Novo Nordisk said it will commit $200 million to the World Diabetes Foundation over 10 years starting in 2027, with funding running through 2036 to expand diabetes prevention, diagnosis and treatment in low- and middle-income countries. The Danish drugmaker’s pledge is aimed at improving access to care in underserved markets, where diabetes burden is rising and health systems often lack screening and treatment capacity. The commitment extends Novo Nordisk’s longstanding backing of the foundation and comes as the company faces growing competition in diabetes and obesity drugs. What to watch next is how the funding is allocated across countries and programs, and whether it translates into measurable gains in diagnosis and treatment rates.